As filed with the Securities and Exchange Commission on March 13, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ENTRADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 81-3983399 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
One Design Center Place Suite 17-500 Boston, MA | 02210 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan
Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan
(Full title of the plans)
Dipal Doshi
Chief Executive Officer
Entrada Therapeutics, Inc.
One Design Center Place
Suite 17-500
Boston, MA 02210
(Name and address of agent for service)
(857) 520-9158
(Telephone number, including area code, of agent for service)
Copies to:
Kingsley L. Taft
Sarah Ashfaq
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |
| Non-accelerated filer | x | Smaller reporting company | x | |
| Emerging growth company | x | |||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this “Registration Statement”) is filed for the purposes of registering (i) an additional 1,338,081 shares of common stock, par value $0.0001 per share (the “common stock”), of Entrada Therapeutics, Inc. (the “Registrant”) that may be issued pursuant to the Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) and (ii) an additional 334,520 shares of common stock that may be issued pursuant to the Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The number of shares of common stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) such number of shares of common stock as determined by the Administrator (as defined in the 2021 Plan). Accordingly, on January 1, 2024, the number of shares of common stock reserved and available for issuance under the 2021 Plan increased by 1,338,081. This Registration Statement registers these additional 1,338,081 shares of common stock. The additional shares are of the same class as other securities relating to the 2021 Plan for which the Registrant’s registration statements filed on Form S-8 (File No. 333-260563, File No. 333-263556 and File No. 333-270286) filed with the Securities and Exchange Commission (the “SEC”) on October 28, 2021, March 15, 2022 and March 6, 2023, respectively, are effective. The number of shares of common stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) 557,524 shares of common stock, (ii) one percent (1%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the Administrator (as defined in the 2021 ESPP). Accordingly, on January 1, 2024, the number of shares of common stock reserved and available for issuance under the 2021 ESPP increased by 334,520. This Registration Statement registers these additional 334,520 shares of common stock. The additional shares are of the same class as other securities relating to the 2021 ESPP for which the Registrant’s registration statements filed on Form S-8 (File No. 333-260563, File No. 333-263556 and File No. 333-270286) filed with the SEC on October 28, 2021, March 15, 2022 and March 6, 2023, respectively, are effective. The information contained in the Registrant’s registration statements on Form S-8 (File No. 333-260563, File No. 333-263556 and File No. 333-270286) is hereby incorporated by reference pursuant to General Instruction E, except for “Item 8. Exhibits.”
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 8. | Exhibits. |
See the Exhibit Index for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| * | Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 13th day of March, 2024.
| ENTRADA THERAPEUTICS, INC. | ||
| By: | /s/ Dipal Doshi | |
| Name: | Dipal Doshi | |
| Title: | Chief Executive Officer (Principal Executive Officer) | |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Dipal Doshi and Kory Wentworth as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their capacities and on the date indicated below.
| Name | Title | Date | ||
| /s/ Dipal Doshi | Chief Executive Officer and Director | March 13, 2024 | ||
| Dipal Doshi | (Principal Executive Officer) | |||
| /s/ Kory Wentworth | Chief Financial Officer | March 13, 2024 | ||
| Kory Wentworth | (Principal Financial and Accounting Officer) | |||
| /s/ Kush M. Parmar, M.D., Ph.D. | Chairman and Director | March 13, 2024 | ||
| Kush M. Parmar, M.D., Ph.D. | ||||
| /s/ Gina Chapman | Director | March 13, 2024 | ||
| Gina Chapman | ||||
| /s/ Peter S. Kim, Ph.D. | Director | March 13, 2024 | ||
| Peter S. Kim, Ph.D. | ||||
| /s/ Mary Thistle | Director | March 13, 2024 | ||
| Mary Thistle | ||||
| /s/ Bernhardt Zeiher, M.D. | Director | March 13, 2024 | ||
| Bernhardt Zeiher, M.D. |
